A Randomized, Double-blind, Single-dose, Dose-escalated Phase Ia Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Recombinant Human Serum Albumin in Healthy Subjects
Latest Information Update: 19 Jan 2023
At a glance
- Drugs Recombinant human serum albumin (Primary)
- Indications Ascites
- Focus Adverse reactions
- Sponsors Protgen
Most Recent Events
- 12 Jan 2023 Status changed from recruiting to completed.
- 11 Jan 2022 New trial record